Politics
Investing
Tech News
Stock
Editor’s Pick

Acceleration of RAD204 Phase 1 dose escalation trial

by admin May 12, 2025

by admin May 12, 2025 0 comment

Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial

Download the PDF here.

This post appeared first on investingnews.com

0 comment

0

Facebook Twitter Pinterest Email

admin

previous post

Cargo thieves are attacking the U.S. supply chain at alarming rates

next post

Fortnite applies to launch on Apple’s App Store after Epic Games court win

You may also like

Multiple New Multi-Commodity Targets

May 12, 2025

Crypto Market Recap: Bitcoin Breaks US$100,000, Coinbase Makes...

May 11, 2025

Tech 5: OpenAI Restructures, Apple Pursues AI Search,...

May 11, 2025

Investing in Uranium ETFs: 9 Options for Uranium...

May 10, 2025

Buffett Hands Over Reins, What’s Next for Berkshire’s...

May 10, 2025

NorthStar Gaming Announces Receipt of Management Cease Trade...

May 9, 2025

US Policy Momentum, Clinical Progress Fueling Psychedelics Market...

May 9, 2025

Group Eleven Intersects 12.0m of 2.30% Cu and...

May 8, 2025

SAGA Metals Extends Claims at the Radar Ti-V-Fe...

May 8, 2025

Copper Crunch: China’s Stockpiles Depleting, US Demand Rising

May 7, 2025

Join The Exclusive Subscription Today And Get Premium Articles For Free

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

Fortnite applies to launch on Apple’s App Store after Epic Games court win

May 12, 2025
Acceleration of RAD204 Phase 1 dose escalation trial

May 12, 2025
Multiple New Multi-Commodity Targets

May 12, 2025
Cargo thieves are attacking the U.S. supply chain at alarming rates

May 11, 2025
Week Ahead: NIFTY Stays In Technically Challanging Environment; Price Action Against These Levels Crucial

May 11, 2025

About us
Contact us
Privacy Policy
Terms & Conditions

Copyright © 2025 metafirstinvest.com | All Rights Reserved

Politics
Investing
Tech News
Stock
Editor’s Pick